| P2093 | author name string | Konstantinos Hatzimouratidis | |
| P2860 | cites work | Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation | Q28274474 |
| | Characterization and functional role of androgen-dependent PDE5 activity in the bladder | Q28582132 |
| | Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinic | Q30650324 |
| | Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies | Q30656693 |
| | Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment | Q33289952 |
| | Sexual dysfunction in the United States: prevalence and predictors | Q33852255 |
| | Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial | Q34002418 |
| | The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics | Q34006676 |
| | Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial | Q34631882 |
| | Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies | Q35008442 |
| | A prospective study of lower urinary tract symptoms and erectile dysfunction | Q35552860 |
| | Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). | Q36144545 |
| | Erectile dysfunction and lower urinary tract symptoms secondary to BPH. | Q36144550 |
| | Lower urinary tract symptoms and sexual dysfunction: a common approach | Q37097048 |
| | The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors | Q37265714 |
| | Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action | Q37833959 |
| | Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. | Q37897389 |
| | Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. | Q39571055 |
| | Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. | Q39897771 |
| | Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction | Q43158898 |
| | Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial | Q43186897 |
| | Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment | Q43280722 |
| | Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis | Q43566603 |
| | Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder | Q43657508 |
| | Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study | Q43678868 |
| | Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study | Q44246967 |
| | Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction | Q44297429 |
| | Lower urinary tract symptoms (LUTS) and sexual function in both sexes | Q44971829 |
| | Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction | Q45216594 |
| | Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. | Q46028384 |
| | Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue | Q46088629 |
| | Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha | Q46137128 |
| | Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study | Q46475553 |
| | A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia | Q46748674 |
| | Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum | Q46790515 |
| | The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies | Q47808331 |
| | Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats | Q51535076 |
| | Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. | Q53102211 |
| | Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tams | Q53117156 |
| | Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. | Q53135300 |
| | Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). | Q53295449 |
| | Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. | Q54355911 |
| | The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study | Q56994963 |
| | The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study | Q57214575 |
| | Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother | Q59830662 |
| | Association between the Bothersomeness of Lower Urinary Tract Symptoms and the Prevalence of Erectile Dysfunction | Q59830832 |
| | EFFECT OF LOWER URINARY TRACT SYMPTOMS ON THE INCIDENCE OF ERECTILE DYSFUNCTION | Q59830846 |
| | Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity | Q73764160 |
| | Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study | Q73839388 |
| | Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study | Q73866764 |
| | Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey" | Q79195963 |
| | Unexpected insights into pelvic function following phosphodiesterase manipulation--what's next for urology? | Q79256053 |
| | Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey | Q79831249 |
| | Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia | Q80029142 |
| | Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study | Q83229163 |
| | Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial | Q83380051 |
| | Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects | Q83961760 |
| | Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study | Q85061476 |
| | Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial | Q85309675 |
| P433 | issue | 4 | |
| P921 | main subject | erectile dysfunction | Q184674 |
| | prostatic hypertrophy | Q506659 |
| P304 | page(s) | 135-147 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | Therapeutic advances in urology | Q26842184 |
| P1476 | title | A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction | |
| P478 | volume | 6 | |